Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

HN011

Trial Overview

Official Title

A Randomized Phase II Study of Nivolumab Versus Nivolumab and Relatlimab as Maintenance Treatment After First-Line Treatment with Platinum-Gemcitabine-Nivolumab for Patients with Epstein-Barr Virus-Associated Recurrent/Metastatic Nasopharyngeal Carcinoma (REMAIN)

Study Purpose

To determine if adding Relatlimab to Nivolumab maintenance therapy improves progression-free survival following first-line treatment of recurrent and/or metastatic nasopharyngeal carcinoma.

Diagnosis

Epstein-Barr Virus-Associated Recurrent/Metastatic Nasopharyngeal Carcinoma

Eligibility

No prior treatment for recurrent disease, no prior PD-L1 medication, no curative-intent surgical or radiation therapy options.

 

Intervention

Nivolumab Versus Nivolumab + Relatlimab as Maintenance Treatment After First-Line Treatment with Platinum-Gemcitabine-Nivolumab

 

For more information, visit

Clinicaltrials.gov

Key Participation Requirements
Trial Location(s)
Methodist Estabrook Cancer Center Methodist Jennie Edmundson Hospital
Gender
Male or Female
Age
19 and older
Enrollment Status
Recruiting
Phase
Phase II